Physician profile
Aliya W Khan
NPI 1366473654
$632.19
in general payments reported to CMS, 2019-2025
12 companies · $599 in 2025
The $599 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.49 · 2024: $17.00 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $223.93 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $175.14 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $40.72 | 2025 | |
| Sanofi-Aventis U.S. LLC | $39.89 | 2025 | |
| Insulet Corporation | $26.49 | 2025 | Omnipod |
| Chiesi USA, INC. | $24.50 | 2025 | Myalept |
| Almatica Pharma LLC | $18.53 | 2025 | Loreev Xr |
| Medtronic, INC. | $17.54 | 2025 | Minimed 780g |
| Merck Sharp & Dohme LLC | $17.00 | 2024 | Capvaxive |
| Ibsa Pharma INC. | $16.88 | 2025 | Flector, Licart, Tirosint |
| Novo Nordisk INC | $16.49 | 2020 | |
| Xeris Pharmaceuticals, INC. | $15.08 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliya Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.